The NeurologyLive® The team spoke with hundreds of experts in the field of neuroscience. Top it off with hundreds of hours of interview clips posted throughout the year. Staff spoke with neurologists, investigators, advanced practice providers. Physiotherapists, advocates, patients, pharmacists and industry professionals—everyone involved in the clinical delivery process.
These conversations take place with individuals from all over the world. both virtually and face to face The team has attended more than 10 of the medical association’s annual meetings, each time meeting with on-site experts to learn more about the conversations that drive care and the challenges that must be overcome.
From those in the movement disorders field this year. We learned about recent pharmaceutical efforts to complete the gold standard treatment for Parkinson’s disease, levodopa; Highlights of the Advanced Therapeutics in Movement and Related Disorders (ATMRD) Conference Advances Biomarker Science A gap remains in the care of movement disorders. Especially in women and many others.
Here, we’ll focus on interviews with the most viewed experts. NeurologyLive® this year. Click the button for more conversations with these experts.
1. RISE-PD Study of IPX-203 in Parkinson’s Disease: Robert A. Hauser, MD, MBA.
The director of the Center for Parkinson’s Disease and Movement Disorders at the University of South Florida detailed the data presented in AAN 2022 and the potential of IPX-203 in Parkinson’s disease. Watch time: 3 minutes
“[With] The main outcome measure of a good time increase Many people look at it and say, ‘Well, 0.53 hours is exactly half an hour increments. Not that much per day.’ But you have to remember patients received IPX-203 three times per day, compared to an average of five IR CD-LD per day.”
2. Highlights of Advanced Therapy in Movement and Related Disorders Congress: Jean Hubble, MD.
A semi-retired neurologist and consultant to the PMD Alliance, offers her comments from the 2022 ATMRD Conference in Washington, D.C., and her advice for young physicians entering the field. Watch time: 3 minutes
“Being in this room with fellow APPs and senior residents is very exciting. I learned a lot from them too. Especially APPs because they see the medical and care of these individuals in a very different way than me. Either in my role as an academic or in industry.”
3. Interdisciplinary Care and Hot Issues in Movement Disorders: Jill Farmer, DO, MPH.
Director of the Parkinson’s Disease and Movement Disorders Program at the Global Neuroscience Institute discusses the importance of a multidisciplinary approach to the management of movement disorders and a popular topic of conversation at ATMRD. Watch time: 2 minutes
“No one can be an expert in everything. You will have a doctor or an APP. [as] Someone who plays a clinical role alongside someone who will deal with social issues, such as a social worker or therapist. and someone who will oversee the recovery strategy.”
4. The Future of Tears as a Biomarker for Neurodegenerative Disorders: Mark Lew, MD.
Director of the Division of Movement Disorders at USC Keck School of Medicine has provided insights into the next steps in how we can amplify tears as a valuable biomarker for degenerative diseases. of the nervous system Watch time: 4 minutes
“It is extremely important if we have biomarkers. It can distinguish between Parkinson’s disease and atypical syndrome, both in synucleinopathies and tauopathies. We have to look at [multiple system atrophy],Lewiy body disease, [progressive supranuclear palsy]and corticobasal syndrome as well.”
5. Knowledge gap in the treatment of women with Parkinson’s disease: Indu Subramanian, MD.
director of the Center for Parkinson’s Disease Research, Education and Clinics in Southwestern Virginia and a clinical professor of neurology at UCLA, noting the lack of a more focused and specific approach to the care of women with Parkinson’s disease. Watch time: 6 minutes
“If you think of the ER or anyone else who sees that patient in urgent care, that might be a single point of care. They don’t think someone who looks like me can get Parkinson’s if they walk in with all sorts of symptoms. very classic The perception of the disease and the social perception of people with Parkinson’s disease really has to change.”
6. Future plans, goals for Prime PD: Konstantin Karmazin, MD.
Chief Medical Officer of Prime PD, the new digital health studio for people with Parkinson’s disease. has detailed future initiatives for this platform. Watch time: 4 minutes
“In general Exercise is good for everyone. The nervous system, in particular, responds really well. As the evidence develops — hopefully in the next year or 2 — we’ll be more open to MS. [multiple sclerosis] Exercise, fitness programs and stuff like that.”
7. The Need for Managing Non-Motor Symptoms in Parkinson’s Disease: Neal Hermanowicz, MD.
Neuroscientists at Christus St. Vincent Health System have provided insight into the critical need for new drugs for both the movement and non-movement symptoms of Parkinson’s disease. Watch time: 3 minutes
“Another notable symptom that I hear from my patients all the time is fatigue. And we don’t understand where it came from. What do we do with that?”
8. Awareness of Botulinum Toxin in Autoimmune Movement Disorders: Laxman Bahroo, DO.
Adjunct Professor of Neurology and Co-Director of the Neurology Residency Program at MedStar Georgetown University Hospital shared his thoughts on the 2022 ATMRD Conference and next steps in recognizing patients’ treatment options. Watch time: 3 minutes
“Botulinum toxin has been around for over 30 years, but it’s still new. That’s the amazing thing about it. Every day I see a patient come in and tell me, ‘How long has this been going on? This is the first time I’ve been injected.’ I hate to tell them this has been around for about 30 years, but awareness about botulinum toxin continues to grow.”
9. Exercise virtual reality and Revealing Parkinson’s Symptoms: Jay Alberts, PhD
Edward F. and Barbara A. Bell Chair at the Cleveland Clinic details how a new virtual reality tool helps explain visceral symptoms from Parkinson’s patients. Watch time: 3 minutes
“What we’re doing now is gathering information that will eventually raise a red or yellow flag. So you go see a neurologist because your vital signs look a little abnormal. That’s exactly what we hope to do.”
10. PreciseDx AI Morphology Feature Array for Detecting Parkinson’s Disease Pathology: John F. Crary, MD, PhD; Gerardo Fernandez Dr.
Neuroscientists at Mount Sinai and Chief Scientific Officer of Precise Dx share background information on the ability of artificial intelligence to improve the diagnosis of Parkinson’s disease from peripheral tissue biopsies. Watch time: 9 minutes
“One of the key points about [identifying pathology in peripheral tissue] is that pathology is very rare. Screening these slides and searching for their distal axons is very time consuming and difficult. I was trained to work with other neuroscientists on the project, but all the time I thought ‘There has to be a better way to do this. It would be great if we could train the AI to do this.’ That’s where the project came from.”